COVID-19-induced Dyslipidemia and Disease Severity: Perspectives from Southern Nigeria



Abstract Views
186

Downloads
205

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Mar 28, 2023
Published May 11, 2023
10.24018/clinicmed.2023.4.3.278

Abstract viewed = 186 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Background: The relationship between dyslipidemia and the severity of coronavirus disease 2019 (COVID-19) has extensively been characterized in the Western population with a dearth of data among Nigerians. Hence, the current study evaluated the lipid/lipoprotein disorders inherent in COVID-19 and its relationship with disease severity among Nigerians.

Methods: This was a retrospective study conducted among 600 patients with RT-PCR-confirmed COVID-19 at the Eleme COVID-19 treatment facility in Port Harcourt, Southern Nigeria. Data were obtained from medical records using validated acquisition templates and analyzed based on lipid/lipoprotein abnormalities and disease severity status.

Results: Among those studied, 54.7% had dyslipidemia while others were normolipidemic. HDL-C dyslipidemia was the most common with a preponderance of hypoalphalipoproteinemia (84.4%). Dyslipidemia afflicted mostly middle-aged, males, urban dwellers, the overweight, and those with classic COVID-19-induced respiratory symptoms. Dyslipidemic cohorts had higher pro-calcitonin, C-reactive protein, D-dimer, total white cell count, and neutrophils, but lower albumin, lymphocyte, and platelet counts compared to the normolipidemic cohorts. Dyslipidemic cohorts with concurrent severe COVID-19 had lower levels of TChol, Tg, HDL-C, and LDL-C levels compared to patients with the less-severe disease. HDL-C was the only lipid/lipoprotein parameter that was associated with severe COVID-19 on crude (OR:8.65; CI:5.96-11.44; p<0.001) and adjusted (OR:8.11; CI:5.65-10.87; p<0.001) regression models compared to other lipid/lipoprotein indices. At 96.77% sensitivity and 89.20% specificity, HDL-C had robust predictive potentials (AUC:0.97; CI:0.84-1.00; p<0.001) over COVID-19 severity.

Conclusion: Dyslipidemia is frequent among those presenting with COVID-19 in association with disease severity, especially among the HDL-C dyslipidemic cohorts. Hence, these findings should be factored in during COVID-19 treatment among Nigerians with the disease.

Keywords: COVID-19 COVID-19 severity dyslipidemia

References

  1. Cabestan JP. The COVID-19 Health Crisis and Its Impact on China’s International Relations. J Risk Financ Manag. 2022; 15(3): 123.
     Google Scholar
  2. Hupert N, Marín-Hernández D, Gao B, Águas R, Nixon DF. Heterologous vaccination interventions to reduce pandemic morbidity and mortality: Modeling the US winter 2020 COVID-19 wave. PNAS. 2022; 119(3): e2025448119.
     Google Scholar
  3. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109: 102433.
     Google Scholar
  4. Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Sci Total Environ. 2020; 730: 138996.
     Google Scholar
  5. He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. The clinical course and its correlated immune status in COVID-19 pneumonia. J Clin Virol. 2020; 127: 104361.
     Google Scholar
  6. Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of COVID‐19 severity: a literature review. Rev in Med Virol. 2021; 31(1): 1-0.
     Google Scholar
  7. Li G, Zhou Y, Ji J, Liu X, Jin Q, Zhang L. Surging publications on the COVID-19 pandemic. Clin Microbiol Infect. 2021; 27(3): 484-6.
     Google Scholar
  8. Masana L, Correig E, Ibarretxe D, Anoro E, Arroyo JA, Jericó C, et al; STACOV-XULA research group. Low HDL and high triglycerides predict COVID-19 severity. Sci Rep. 2021; 11(1): 7217.
     Google Scholar
  9. Alcántara-Alonso E, Molinar-Ramos F, González-López JA, Alcántara-Alonso V, Muñoz-Pérez MA, Lozano-Nuevo JJ, et al. High triglyceride to HDL-cholesterol ratio as a biochemical marker of severe outcomes in COVID-19 patients. Clin Nutr ESPEN. 2021; 44: 437-444.
     Google Scholar
  10. Wang G, Zhang Q, Zhao X, Dong H, Wu C, Wu F, et al. Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study. Lipids Health Dis. 2020; 19(1): 204.
     Google Scholar
  11. Huang S, Zhou C, Yuan Z, Xiao H, Wu X. The clinical value of high-density lipoprotein in the evaluation of new coronavirus pneumonia. Adv Clin Exp Med. 2021; 30(2): 153-156.
     Google Scholar
  12. Omunakwe HE, Bob-Manuel M, Enyinnaya SO, Kattey KA, Kpaluku CA. Asymptomatic COVID Infections in Port Harcourt, Nigeria. Niger J Med. 2021; 30(6): 675-7.
     Google Scholar
  13. Nigerian Centre for Disease Control (NCDC) National Interim Guidelines for Clinical Management of COVID-19. Accessed 25th December, 2022.
     Google Scholar
  14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285(19): 2486-97.
     Google Scholar
  15. Chang MC, Park YK, Kim BO, Park D. Risk factors for disease progression in COVID-19 patients. BMC Infect Dis. 2020; 20(1): 445.
     Google Scholar
  16. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020; 369: m1966.
     Google Scholar
  17. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020; 28: 1195-1199.
     Google Scholar
  18. Moukaila AR, Bawe LD, Mossi KE, Nemi KD, Kotosso A , Tsevi Yawovi Mawufemo TY, et al. Dyslipidemia in patients with COVID-19 in Togo. Int J Intern Med. 2022; 11(1): 47-53.
     Google Scholar
  19. Atmosudigdo IS, Lim MA, Radi B, Henrina J, Yonas E, Vania R, et al. Dyslipidemia increases the risk of severe COVID-19: a systematic review, meta-analysis, and meta-regression. Clin Med Insights: Endocrinol Diabetes. 2021; 14: 1179551421990675.
     Google Scholar
  20. Amadi C, Lawson S, Amadi B, Agbo E. Correlation of plasma albumin status with markers of hepato-biliary dysfunction and Systemic Inflammation Among COVID-19 Patients. Biomed Sci. 2022; 8 (1): 41-48.
     Google Scholar
  21. Amadi C, Lawson S. The Impact of Systemic Inflammation on Sex-based Bias Following SARS-CoV-2 Infection. Eur J Clin Biomed Sci. 2022; 8(1): 1-8.
     Google Scholar
  22. Lawson S, Amadi C. Assessment of surrogate markers/indices of inflammation among COVID-19 patients with and without comorbid conditions. Am J Lab Med. 2022; 7(1): 16-22.
     Google Scholar
  23. Lawson S, Amadi C. Potentials of varied inflammatory indices in the prediction of COVID-19 severity among Nigerians. Adv Biochem. 2022; 10(1); 18-24.
     Google Scholar
  24. Almas T, Malik J, Alsubai AK, Ehtesham M, Laique T, Ishaq U, et al. Effect of COVID-19 on lipid profile parameters and its correlation with acute phase reactants: A single-center retrospective analysis. Ann Med Surg. 2022: 103856.
     Google Scholar
  25. Wei X, Zeng W, Su J, Wan H, Yu X, Cao X, et al. Hypolipidemia is associated with the severity of COVID-19. J Clin Lipidol. 2020; 14: 297-304.
     Google Scholar
  26. Chidambaram V, Kumar A, Majella MG, Seth B, Sivakumar RK, Voruganti D, et al. HDL cholesterol levels and susceptibility to COVID-19. EBioMedicine. 2022: 104166.
     Google Scholar
  27. Hu X, Chen D, Wu L, He G, Ye W. Declined serum high-density lipoprotein cholesterol is associated with the severity of COVID-19 infection. Clin Chim Acta. 2020; 510: 105-110.
     Google Scholar
  28. Atmosudigdo IS, Lim MA, Radi B, Henrina J, Yonas E, Vania R, et al. Dyslipidemia Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-regression. Clin Med Insights Endocrinol Diabetes. 2021; 14: 1-7.
     Google Scholar
  29. Choi GJ, Kim HM, Kang H. The Potential Role of Dyslipidemia in COVID-19 Severity: an Umbrella Review of Systematic Reviews. J Lipid Atheroscler. 2020; 9(3): 435-448.
     Google Scholar


Most read articles by the same author(s)